Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Management
Scientific Advisory Board
Corporate Directory
Corporate Governance
Pipeline
Amplia's Pipeline
Amplia's Cancer Program
Amplia's Fibrosis Program
Investor Information
Welcome
Investor Fact Sheet
Investor Presentation
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Annual General Meeting
Announcements and Reports
ASX Announcements
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Investor Information
Home
>
Investor Information
>
Media
Welcome
Investor Fact Sheet
Investor Presentation
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Annual General Meeting
Media
26-Jul-2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
26-Jul-2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
21-Jul-2021
Amplia Therapeutics returns successful phase one trial results
19-Jul-2021
Garvan's June Seminar: The Power of Personalised Medicine
30-Jun-2021
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
28-Jun-2021
Amplia Therapeutics and Sydney’s Garvan Institute enter collaboration agreement for pancreatic cancer treatment
2-Jun-2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
18-Mar-2021
Amplia Therapeutics (ASX:ATX) signs agreement with Garvan Institute
17-Mar-2021
Amplia Therapeutics (ASX:ATX) completes single-dose study of AMP945
14-Oct-2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
9-Oct-2020
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
